Literature DB >> 34761455

Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Jothi Anantharajan1, Nithya Baburajendran1, Grace Lin1, Yong Yao Loh1, Weijun Xu1, Nur Huda Binte Ahmad1, Shuang Liu1,2, Anna E Jansson1, John Wee Liang Kuan1, Elizabeth Yihui Ng1, Yee Khoon Yeo1, Alvin W Hung1, Joma Joy1, Jeffrey Hill1, Heide L Ford3, Rui Zhao4, Thomas H Keller1, CongBao Kang1.   

Abstract

Human eyes absent (EYA) proteins possess Tyr phosphatase activity, which is critical for numerous cancer and metastasis promoting activities, making it an attractive target for cancer therapy. In this work, we demonstrate that the inhibitor-bound form of EYA2 does not favour binding to Mg2+ , which is indispensable for the Tyr phosphatase activity. We further describe characterization and optimization of this class of allosteric inhibitors. A series of analogues were synthesized to improve potency of the inhibitors and to elucidate structure-activity relationships. Two co-crystal structures confirm the binding modes of this class of inhibitors. Our medicinal chemical, structural, biochemical, and biophysical studies provide insight into the molecular interactions of EYA2 with these allosteric inhibitors. The compounds derived from this study are useful for exploring the function of the Tyr phosphatase activity of EYA2 in normal and cancerous cells and serve as reference compounds for screening or developing allosteric phosphatase inhibitors. Finally, the co-crystal structures reported in this study will aid in structure-based drug discovery against EYA2.
© 2021 The Protein Society.

Entities:  

Keywords:  EYA2; allosteric inhibitor; phosphatase inhibitor; protein binding; protein structure

Mesh:

Substances:

Year:  2021        PMID: 34761455      PMCID: PMC8819961          DOI: 10.1002/pro.4234

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  30 in total

1.  Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis.

Authors:  Xue Li; Kenneth A Oghi; Jie Zhang; Anna Krones; Kevin T Bush; Christopher K Glass; Sanjay K Nigam; Aneel K Aggarwal; Richard Maas; David W Rose; Michael G Rosenfeld
Journal:  Nature       Date:  2003-11-20       Impact factor: 49.962

Review 2.  Protein tyrosine phosphatases: from genes, to function, to disease.

Authors:  Nicholas K Tonks
Journal:  Nat Rev Mol Cell Biol       Date:  2006-11       Impact factor: 94.444

3.  Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.

Authors:  Aaron B Krueger; David J Drasin; Wendy A Lea; Aaron N Patrick; Samarjit Patnaik; Donald S Backos; Christopher J Matheson; Xin Hu; Elena Barnaeva; Michael J Holliday; Melanie A Blevins; Tyler P Robin; Elan Z Eisenmesser; Marc Ferrer; Anton Simeonov; Noel Southall; Philip Reigan; Juan Marugan; Heide L Ford; Rui Zhao
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

4.  Upregulation of notch2 and six1 is associated with progression of early-stage lung adenocarcinoma and a more aggressive phenotype at advanced stages.

Authors:  Takahiro Mimae; Morihito Okada; Man Hagiyama; Yoshihiro Miyata; Yasuhiro Tsutani; Takao Inoue; Yoshinori Murakami; Akihiko Ito
Journal:  Clin Cancer Res       Date:  2011-12-21       Impact factor: 12.531

Review 5.  The SIX1-EYA transcriptional complex as a therapeutic target in cancer.

Authors:  Melanie A Blevins; Christina G Towers; Aaron N Patrick; Rui Zhao; Heide L Ford
Journal:  Expert Opin Ther Targets       Date:  2015-01-02       Impact factor: 6.902

6.  The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells.

Authors:  R N Pandey; R Rani; E-J Yeo; M Spencer; S Hu; R A Lang; R S Hegde
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

7.  Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Authors:  Jothi Anantharajan; Nithya Baburajendran; Grace Lin; Yong Yao Loh; Weijun Xu; Nur Huda Binte Ahmad; Shuang Liu; Anna E Jansson; John Wee Liang Kuan; Elizabeth Yihui Ng; Yee Khoon Yeo; Alvin W Hung; Joma Joy; Jeffrey Hill; Heide L Ford; Rui Zhao; Thomas H Keller; CongBao Kang
Journal:  Protein Sci       Date:  2021-11-18       Impact factor: 6.725

Review 8.  The Eya phosphatase: Its unique role in cancer.

Authors:  Hengbo Zhou; Lingdi Zhang; Rebecca L Vartuli; Heide L Ford; Rui Zhao
Journal:  Int J Biochem Cell Biol       Date:  2017-09-05       Impact factor: 5.085

9.  Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.

Authors:  S M Farabaugh; D S Micalizzi; P Jedlicka; R Zhao; H L Ford
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

10.  EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN.

Authors:  Zhaoming Li; Ran Qiu; Xia Qiu; Tian Tian
Journal:  Oncotarget       Date:  2017-12-02
View more
  1 in total

1.  Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase.

Authors:  Jothi Anantharajan; Nithya Baburajendran; Grace Lin; Yong Yao Loh; Weijun Xu; Nur Huda Binte Ahmad; Shuang Liu; Anna E Jansson; John Wee Liang Kuan; Elizabeth Yihui Ng; Yee Khoon Yeo; Alvin W Hung; Joma Joy; Jeffrey Hill; Heide L Ford; Rui Zhao; Thomas H Keller; CongBao Kang
Journal:  Protein Sci       Date:  2021-11-18       Impact factor: 6.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.